.Merck beats earnings assumptions, increases sales expectation on strong need for leading drugs like Keytruda CNBCMerck & Co. (MRK United States) Trumps Earnings Forecasts as Keytruda Sales Increase BloombergMerck Stock: Pharma Titan Posts Powerful Results, But Expectation Falls Short Capitalist's Company DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck defeats income and also sales assumptions amidst Keytruda advantage, however delivers mixed full-year overview MarketWatch.